Research Topics
| R G HollowaySummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Estimating and communicating prognosis in advanced neurologic diseaseRobert G Holloway
Departments of Neurology and Community and Preventive Medicine, University of Rochester, NY, USA
Neurology 80:764-72. 2013..Confronting the challenges of prognosis is necessary to fulfill the promise of delivering high-quality, patient-centered care...
Getting to value in neurological care: a roadmap for academic neurologyRobert G Holloway
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Ann Neurol 69:909-18. 2011..By highlighting progress made and the challenges that lie ahead, we hope to create a clinical, educational, and research roadmap for academic departments of neurology to thrive in today's increasingly regulated environment...
The safety of hospital stroke careRobert G Holloway
Office of Clinical Practice Evaluation, Strong Memorial Hospital, NY, USA
Neurology 68:550-5. 2007..To analyze medical errors and adverse events occurring in stroke patients and to provide insights into system or stroke-specific processes that can be modified to reduce the likelihood of error and patient harm...- Prognosis and decision making in severe strokeRobert G Holloway
Department of Neurology, University of Rochester School of Medicine, Rochester, NY 14642, USA
JAMA 294:725-33. 2005..An increasing number of deaths following severe stroke are due to terminal extubations. Variation in withdrawal-of-care practices suggests the possibility of unnecessary prolongation of suffering or of unwanted deaths... - Palliative care consultations in hospitalized stroke patientsRobert G Holloway
Department of Neurology, Division of Palliative Care, University of Rochester Medical Center, Rochester, New York 14642, USA
J Palliat Med 13:407-12. 2010..To determine the pattern and characteristics of palliative care (PC) consultations in patients with stroke and compare them with the characteristics of nonstroke consultations... - Invited Article: Conflicts of interest for authors of American Academy of Neurology clinical practice guidelinesR G Holloway
Department of Neurology, University of Rochester, 601 Elmwood Avenue, Box 673, Rochester, NY 14642, USA
Neurology 71:57-63. 2008..Clinical practice guidelines (CPGs) shape clinical care worldwide but are prone to potential error and bias due to conflicts of interest (COI)... - Mortality as a measure of quality: implications for palliative and end-of-life careRobert G Holloway
Department of Neurology, University of Rochester, Rochester, NY 14642, USA
JAMA 298:802-4. 2007 - Quantitative risk-benefit analysis of natalizumabJ P Thompson
Department of Neurology, University of Rochester, Rochester, NY, USA
Neurology 71:357-64. 2008..To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS)... - Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trialKatia Noyes
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York, USA
Med Decis Making 24:472-85. 2004..If initial pramipexole results in long-term improvements in quality of life, its cost-effectiveness will become more favorable... - Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030E R Dorsey
Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
Neurology 68:384-6. 2007..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030... - Health care costs decline after successful epilepsy surgeryJ T Langfitt
Department of Neurology, University of Rochester, Rochester, NY 14642, USA
Neurology 68:1290-8. 2007..There is little information about how health care costs are affected by evaluation and surgery... - Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosisE R Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
Neurology 68:1524-8. 2007..033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days)... - Development of performance measures for acute ischemic strokeR G Holloway
Department of Neurology, University of Rochester School of Medicine, NY, USA
Stroke 32:2058-74. 2001..The purpose of the present study was to develop and rate performance measures for hospital-based acute ischemic stroke... - A cost-utility comparison of four first-line medications in painful diabetic neuropathyAlec B O'Connor
Department of Medicine, University of Rochester School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, USA
Pharmacoeconomics 26:1045-64. 2008..Painful diabetic neuropathy is common and adversely affects patients' quality of life and function. Several treatment options exist, but their relative efficacy and value are unknown... - Financial anatomy of neuroscience researchE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Ann Neurol 60:652-9. 2006..To estimate the level of funding for neuroscience research from federal and industry sources and to examine the therapeutic advances in the neurosciences over the past decade... - A cost-effectiveness analysis of carotid artery stenting compared with endarterectomyKate C Young
Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA
J Stroke Cerebrovasc Dis 19:404-9. 2010..With 59% probability, CEA will be the optimal intervention when all of the model assumptions are varied simultaneously... - Health state preferences and decision-making after malignant middle cerebral artery infarctionsAdam G Kelly
University of Rochester Medical Center, Department of Neurology, 601 Elmwood Avenue, Box 673, Rochester, NY 14642, USA
Neurology 75:682-7. 2010..The value assigned to health states with significant disability varies widely and may influence decisions regarding hemicraniectomy... - Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patientsSally A Norton
School of Nursing, University of Rochester Medical Center, Rochester, NY, USA
Crit Care Med 35:1530-5. 2007..The purpose of this study was to examine the effect of proactive palliative care consultation on length of stay for high-risk patients in the medical intensive care unit (MICU)... - Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) program sustained over time? A longitudinal comparison of GWTG-CAD hospitals versus non-GWTG-CAD hospitalsYing Xian
Department of Community and Preventive Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA
Am Heart J 159:207-14. 2010..We sought to establish whether these benefits from participation in GWTG-CAD were sustained over time... - The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluationKatia Noyes
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York 14620, USA
Med Decis Making 27:327-34. 2007..The objective of this study is to examine the effect of country-specific EQ-5D preference weights on the cost-effectiveness (CE) of initial pramipexole versus levodopa strategy in patients with Parkinson disease (PD)... - Risk factors for somnolence, edema, and hallucinations in early Parkinson diseaseKevin M Biglan
University of Rochester, Department of Neurology, Rochester, NY 14620, USA
Neurology 69:187-95. 2007..A secondary finding of the trial was a higher than anticipated development or worsening of somnolence and edema and development of hallucinations... - A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgiaAlec B O'Connor
Department of Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA
J Am Geriatr Soc 55:1176-84. 2007..To compare the net health effects and costs resulting from treatment with different first-line postherpetic neuralgia (PHN) medications... - Financing of U.S. biomedical research and new drug approvals across therapeutic areasE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America
PLoS ONE 4:e7015. 2009..We estimated U.S. biomedical research funding across therapeutic areas, determined the association with disease burden, and evaluated new drug approvals that resulted from this investment... - Effects of gabapentin on sleep in menopausal women with hot flashes as measured by a Pittsburgh Sleep Quality Index factor scoring modelMichael E Yurcheshen
Department of Neurology, University of Rochester School of Medicine and Dentistry, Strong Sleep Disorders Center, Rochester, New York 14618, USA
J Womens Health (Larchmt) 18:1355-60. 2009..The aim of this research was to analyze gabapentin's effect on Pittsburgh Sleep Quality Index (PSQI) scores in menopausal women... - Funding of Parkinson research from industry and US federal and foundation sourcesE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
Mov Disord 24:731-7. 2009..These companies will likely require partnerships to drive successful development of new PD therapies... - Public reporting of quality data for stroke: is it measuring quality?Adam Kelly
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
Stroke 39:3367-71. 2008..We reviewed the scope and content of stroke data being reported to the public and how well it captures the quality of stroke care... - Biomarkers in Parkinson's diseaseE Ray Dorsey
University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 223, Rochester, NY 14620, USA
Expert Rev Neurother 6:823-31. 2006..However, to date, biomarkers, despite their considerable promise, have had limited utility in clinical trials and practice... - A review of pramipexole and its clinical utility in Parkinson's diseaseKevin M Biglan
University of Rochester, Department of Neurology, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Expert Opin Pharmacother 3:197-210. 2002..In addition to its use in PD, pramipexole has shown some utility in the treatment of restless legs syndrome (RLS), depression and schizophrenia... - Clinical trial end points: on the road to nowhere?Robert G Holloway
Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14620, USA
Neurology 58:679-86. 2002.... - CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomesRonald H Gottlieb
Dept of Radiology, Univ of Rochester Medical Ctr, NY 14642, USA
Radiology 225:441-9. 2002.... - Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysisScott Y H Kim
Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Am J Psychiatry 160:1272-6. 2003..The authors assessed the cost-effectiveness of entering such a trial from the perspective of potential subjects... - Surrogate endpoints in Parkinson's disease researchKevin M Biglan
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA
Curr Neurol Neurosci Rep 3:314-20. 2003..Finally, the significant challenges that lie ahead for validating and interpreting surrogate endpoints in PD are addressed... - Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialRobert G Holloway
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Arch Neurol 61:1044-53. 2004..The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear... - What is the risk of developing parkinsonism following neuroleptic use?Katia Noyes
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, NY, USA
Neurology 66:941-3. 2006..Although more research is needed, these data suggest that 126 Medicare beneficiaries would need to be treated with neuroleptic medications to cause one additional case of self-reported PD... - Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of lifeKatia Noyes
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, NY 14620, USA
Value Health 9:28-38. 2006..Here we assess the effect of therapy on HRQOL and explore factors that influence the HRQOL profiles and subdomains... - Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectivenessKatia Noyes
Department of Community and Preventive Medicine, University of Rochester School of Medicine, Rochester, New York 14620, USA
Pharmacoeconomics 23:1257-70. 2005..In this article we analyse the dynamic changes in cumulative costs, effects and incremental cost effectiveness of two competing drug strategies in patients with early Parkinson's disease (PD)... - Evidence from cost-effectiveness researchKatia Noyes
Department of Community and Preventive Medicine, University of Rochester, NY 14620, USA
NeuroRx 1:348-55. 2004.... - Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysisK J Tomaszewski
Department of Community and Preventive Medicine, University of Rochester School of Medicine, NY 14642, USA
Neurology 57:663-71. 2001..In treating PD, deep brain stimulation (DBS) has shown great promise in a series of uncontrolled studies... - Initial treatment of early Parkinson's disease: a review of recent, randomized controlled trialsK Biglan
Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Suite 220, Rochester, NY 14620, USA
Curr Neurol Neurosci Rep 1:329-36. 2001.... - Responsiveness of life-threatening refractory emesis to gabapentin-scopolamine therapy following posterior fossa surgery. Case reportThomas Guttuso
Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14214, USA
J Neurosurg 102:547-9. 2005.... - Development and testing of the Parkinson's disease quality of life scaleMickie Welsh
Department of Neurology, University of Southern California, Los Angeles, California, USA
Mov Disord 18:637-45. 2003..Continuing development of the PDQUALIF will be directed at enhancing the psychometric properties, establishing responsiveness and determining appropriateness in culturally diverse samples... - A systematic review of cost-effectiveness research of stroke evaluation and treatmentR G Holloway
Department of Neurology, University of Rochester School of Medicine, Rochester, NY, USA
Stroke 30:1340-9. 1999..This work was undertaken to review research addressing the cost-effectiveness of stroke-related diagnostic, preventive, or therapeutic interventions... - Invited article: Neurology and quality improvement: an introductionC T Bever
Department of Neurology, University of Maryland Hospital, Room N4W46, 22 South Greene Street, Baltimore, MD 21201, USA
Neurology 70:1636-40. 2008 - Selegiline shortage: Causes and costs of a generic drug shortageE R Dorsey
Department of Neurology, University at Buffalo, NY, USA
Neurology 73:213-7. 2009..We sought to evaluate prescription trends of generic selegiline and to quantify the economic impact of any resulting drug substitution of more expensive alternatives... - Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based studyK Noyes
Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
Neurology 77:355-63. 2011..To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients with relapsing multiple sclerosis (MS)... - Employment-seeking experiences of residents in 1996: a window into the neurology marketplaceW L Larson
Department of Neurology, Medical College of Wisconsin, Milwaukee 53226, USA
Neurology 54:214-8. 2000..To assess career choice and employment-seeking experience of senior neurology residents in 1996... - Neurologists' use of ICD-9CM codes for dementiaM Pippenger
Department of Neurology, University of California, Los Angeles, 90095 1769, USA
Neurology 56:1206-9. 2001..Other codes used were not inaccurate but would result in lower reimbursement. Variation in coding could affect validity of dementia research using claims data... - Ethics of sham surgery: perspective of patientsSamuel A Frank
Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA
Mov Disord 23:63-8. 2008..Future research needs to determine whether eliciting more considered judgments of laypersons would reveal different levels of support for sham surgery... - Update in neurologyRobert G Holloway
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Ann Intern Med 144:421-6. 2006 - How much is a good night's sleep worth?Linda S Williams
Stroke 36:1293-4. 2005 - Evidence-based neurotherapeutics: a spectrum of evidenceRobert G Holloway
NeuroRx 1:295-7. 2004 - Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American EpilepsRobert G Holloway
Neurology 64:172-4; author reply 172-4. 2005 - Diffusion tensor imaging: scientific advance, clinical tool, or just a pretty picture?Deborah M Little
Neurology 68:9-10. 2007 - Quality of life in epilepsy, multiple sclerosis, and beyondE Ray Dorsey
Ann Neurol 62:307-8. 2007 - Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendationsChristopher G Goetz
Rush University Medical Center, 1725 W Harrison Street, Chicago, IL 60612, USA
Mov Disord 19:1020-8. 2004..5 increments, this adaptation warrants clinimetric testing. Without such testing, however, the original five-point scales should be maintained...
Research Grants
- Neurology Outcomes Research:Clinical Trials/ TrainingRobert Holloway; Fiscal Year: 2005..Dr. Holloway's position within the Departments of Neurology and Community and Preventive Medicine, and the Rochester Clinical Research Curriculum will ensure the recruitment of highly qualified trainees. ..